EpiCast Report: Hemophilia - Epidemiology Forecast to 2026

  • ID: 4334432
  • Drug Pipelines
  • 39 pages
  • GlobalData
1 of 3
EpiCast Report: Hemophilia - Epidemiology Forecast to 2026

Summary

Hemophilia is an X-linked hereditary bleeding disorder, characterized by impaired blood coagulation as a result of deficiencies in the production or function of coagulation factor VIII (FVIII) in hemophilia A or factor IX (FIX) in hemophilia B (Bolton-Maggs and Pasi, 2003). Because of the deficiency of coagulation factor, hemophilia patients have a tendency for bleeding in joints, muscles, soft tissues, and within mucous membranes, which can be either spontaneous or due to internal or external trauma, depending on the severity of the disease (CDC, 2017b; Mayo Clinic, 2014).

In the 7MM, epidemiologists forecast an increase in the diagnosed prevalent cases of hemophilia A and hemophilia B, from 51,627 diagnosed prevalent cases in 2016 to 52,566 diagnosed prevalent cases in 2026, with an Annual Growth Rate (AGR) of 0.18% during the forecast period. The US will have the highest number of diagnosed prevalent cases of hemophilia A and hemophilia B among the 7MM throughout the forecast period, while Spain will have the lowest.

Among the 7MM in 2016, the UK had the highest age-standardized diagnosed prevalence of hemophilia A in men with 20.36 cases per 100,000 population and in women with 0.60 cases per 100,000 population. The age-standardized diagnosed prevalence of hemophilia A in Germany was lowest in men with 9.61 cases per 100,000 population and in women with 0.28 cases per 100,000 population.

The report "EpiCast Report: Hemophilia - Epidemiology Forecast to 2026" provides an overview of the comorbidities and the global and historical trends for hemophilia in seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of hemophilia segmented by type (hemophilia A and hemophilia B), sex, and age (for all ages) in these markets. The diagnosed prevalent cases of hemophilia A and hemophilia B by severity and with inhibitors were also provided in the report.

Scope
  • The Hemophilia EpiCast Report provides an overview of the risk factors and global trends of hemophilia in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiology forecast of diagnosed prevalent cases of hemophilia segmented by type (hemophilia A and hemophilia B), sex, and age (for all ages) in these seven markets.
  • The hemophilia epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to Buy

The Hemophilia EpiCast report will allow you to -
  • Develop business strategies by understanding the trends shaping and driving the global hemophilia market.
  • Quantify patient populations in the global hemophilia market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for hemophilia therapeutics in each of the markets covered.
  • Identify the percentage of hemophilia prevalent cases by type.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Table of Contents
1.1 List of Tables
1.2 List of Figures
2. Hemophilia: Executive Summary
2.1 Related Reports
2.2 Upcoming Reports
3. Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods
3.4.3 Diagnosed Prevalent Cases
3.4.4 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity
3.4.5 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Inhibitors
3.5 Epidemiological Forecast for Hemophilia A (2016-2026)
3.5.1 Diagnosed Prevalent Cases of Hemophilia A
3.5.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia A
3.5.3 Sex-Specific Diagnosed Prevalent Cases of Hemophilia A
3.5.4 Diagnosed Prevalent Cases of Hemophilia A by Severity
3.5.5 Diagnosed Prevalent Cases of Hemophilia A with Inhibitors
3.6 Epidemiological Forecast for Hemophilia B (2016-2026)
3.6.1 Diagnosed Prevalent Cases of Hemophilia B
3.6.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia B
3.6.3 Sex -Specific Diagnosed Prevalent Cases of Hemophilia B
3.6.4 Diagnosed Prevalent Cases of Hemophilia B by Severity
3.6.5 Diagnosed Prevalent Cases of Hemophilia B with Inhibitors
3.7 Epidemiological Forecast for Hemophilia A and Hemophilia B (2016-2026)
3.7.1 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
3.7.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
3.7.3 Sex -Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
3.7.4 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity
3.7.5 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors
3.8 Discussion
3.8.1 Epidemiological Forecast Insight
3.8.2 Limitations of the Analysis
3.8.3 Strengths of the Analysis
4. Appendix
4.1 Bibliography
4.2 About the Authors
4.2.1 Epidemiologist
4.2.2 Reviewers
4.2.3 Global Director of Therapy Analysis and Epidemiology
4.2.4 Global Head and EVP of Healthcare Operations and Strategy
4.3 About
4.4 Contact Us
4.5 Disclaimer

1.1 List of Tables
Table 1: Relationship of Bleeding Severity with Clotting Factor Level.
Table 2: Comorbidities for Hemophilia
Table 3: 7MM, Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, All Ages, N, Selected Years 2016-2026.
Table 4: 7MM, Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, All Ages, N, Selected Years 2016-2026.
Table 5: 7MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, N, Selected Years 2016-2026.

1.2 List of Figures
Figure 1: 7MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, 2016 and 2026
Figure 2: 7MM, Age-Standardized Diagnosed Prevalence of Hemophilia A (Cases per 100,000 Population), All Ages, 2016
Figure 3: 7MM, Age-Standardized Diagnosed Prevalence of Hemophilia B (Cases per 100,000 Population), All Ages, 2016
Figure 4: 7MM, Sources Used, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
Figure 5: 7MM, Sources Used, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity
Figure 6: 7MM, Sources Used, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors
Figure 7: 7MM, Age-Specific Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, All Ages, N, 2016
Figure 8: 7MM, Sex-Specific Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, All Ages, N, 2016
Figure 9: 7MM, Diagnosed Prevalent Cases of Hemophilia A by Severity, Both Sexes, All Ages, N, 2016
Figure 10: 7MM, Diagnosed Prevalent Cases of Hemophilia A with Inhibitors, Both Sexes, All Ages, N, 2016
Figure 11: 7MM, Age-Specific Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, All Ages, 2016
Figure 12: 7MM, Sex-Specific Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, All Ages, N, 2016
Figure 13: 7MM, Diagnosed Prevalent Cases of Hemophilia B by Severity, Both Sexes, All Ages, N, 2016
Figure 14: 7MM, Diagnosed Prevalent Cases of Hemophilia B with Inhibitors, Both Sexes, All Ages, N, 2016
Figure 15: 7MM, Age-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, N, 2016
Figure 16: 7MM, Sex-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, All Ages, N, 2016
Figure 17: 7MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity, Both Sexes, All Ages, N, 2016
Figure 18: 7MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors, Both Sexes, All Ages, N, 2016
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll